Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Colson

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1992
Phycocyanin alpha-subunit phycocyanobilin lyaseC D Fairchild, J Zhao, J Zhou, et al.
HIV Clinical Trials|April 17, 2007
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyCalvin J Cohen, Amy E Colson, Alexander G Sheble-Hall, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 6, 2002
Male sexual dysfunction associated with antiretroviral therapyAmy E Colson, Marla J Keller, Paul E Sax, et al.
Prevention Science : the Official Journal of the Society for Prevention Research|May 20, 2026
The Effectiveness of the Parent Support Program: a Randomized Controlled Trial of an Online Intervention to Increase Parental Support Among Parents and Caregivers of Trans and Nonbinary YouthEm Matsuno, Matt L Miller, Ga Tin Finneas Wong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2000
Paronychia in association with indinavir treatmentA E Colson, P E Sax, M J Keller, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
Annals of Internal Medicine|December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized StudyAmy E Colson, Gordon E Crofoot, Peter J Ruane, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1992
Phycocyanin alpha-subunit phycocyanobilin lyaseC D Fairchild, J Zhao, J Zhou, et al.
HIV Clinical Trials|April 17, 2007
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyCalvin J Cohen, Amy E Colson, Alexander G Sheble-Hall, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 6, 2002
Male sexual dysfunction associated with antiretroviral therapyAmy E Colson, Marla J Keller, Paul E Sax, et al.
Prevention Science : the Official Journal of the Society for Prevention Research|May 20, 2026
The Effectiveness of the Parent Support Program: a Randomized Controlled Trial of an Online Intervention to Increase Parental Support Among Parents and Caregivers of Trans and Nonbinary YouthEm Matsuno, Matt L Miller, Ga Tin Finneas Wong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2000
Paronychia in association with indinavir treatmentA E Colson, P E Sax, M J Keller, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
Annals of Internal Medicine|December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized StudyAmy E Colson, Gordon E Crofoot, Peter J Ruane, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 3